What is Faze Medicines?
Faze Medicines is a pioneering biotechnology company leveraging the novel science of biomolecular condensates to drive innovation in medicine. Founded by leading experts in the field, the company aims to translate groundbreaking research into tangible medical solutions. Its strategic focus on this emerging area of science suggests a commitment to developing novel therapeutics for complex diseases.
How much funding has Faze Medicines raised?
Faze Medicines has raised a total of $81M across 1 funding round:
Series A
$81M
Series A (2020): $81M with participation from AbbVie Biotech Ventures, Eli Lilly, Alexandria Venture Investments., Catalio Capital Management, Third Rock Ventures, Novartis Venture Fund, Invus, and Casdin Capital
Key Investors in Faze Medicines
AbbVie Biotech Ventures
AbbVie Biotech Ventures is an investment arm focused on advancing research and development within the biotechnology sector, likely seeking innovative companies with strong scientific foundations.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm dedicated to discovering, developing, and commercializing prescription medicines across various therapeutic areas, including diabetes and oncology.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare and biomedical technology companies, investing across private, public, and credit markets.
What's next for Faze Medicines?
The recent major strategic investment signifies a critical growth phase for Faze Medicines. This capital will likely fuel further research and development, potentially expanding its pipeline of therapeutic candidates and advancing preclinical or clinical trials. The company's trajectory, bolstered by significant backing from established entities, indicates a strong potential for future value creation and market impact within the competitive biotechnology landscape.
See full Faze Medicines company page
